Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial).

Marwân-Al-Qays BousmahMarie Libérée NishimweTamara Tovar-SanchezMartial Lantche WandjiMireille Mpoudi-EtameGwenaëlle MaradanPierrette Omgba BassegaMarie VarloteauxAlice MontoyoCharles KouanfackEric DelaporteSylvie Boyernull null

Published in: PharmacoEconomics (2020)

ClinicalTrials.gov Identifier: NCT02777229.

Keyphrases

hiv infected patients
antiretroviral therapy
low dose
hiv infected
clinical trial
high dose
phase iii